2024
Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
Hofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.Peer-Reviewed Original ResearchNon-Hispanic blacksNon-Hispanic whitesSurveillance Epidemiology and End ResultsNational Cancer InstituteWhite patientsBlack menBlack patientsAvailability of diagnosisWhite menStudy start dateEncounter dateSEER dataFace-to-faceHealth systemMultiple myeloma patientsMyeloma patientsOutpatient encountersDeath reportingAge decileSocial Vulnerability IndexWhite womenMatched control groupBlack womenMedian survivalPatient records
2022
Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool
Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Leone J, Vallejo CT, Winer EP, Lin NU, Tayob N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. European Journal Of Cancer 2022, 173: 20-29. PMID: 35841843, DOI: 10.1016/j.ejca.2022.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityHR-positive breast cancerBreast cancerCumulative riskCause mortalityTumor characteristicsRisk of BCSMHormone receptor-positive breast cancerReceptor-positive breast cancerCancer-specific mortalityEnd Results registryLong-term mortalityRisk of deathCancer patient subgroupsPopulation-based riskPathologic variablesInitial diagnosisPatient subgroupsSEER dataPatientsAge groupsCancerMortalityHormone receptorsDiagnosis
2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020, 34: 3338-3347. PMID: 32313109, PMCID: PMC7572530, DOI: 10.1038/s41375-020-0830-0.Peer-Reviewed Original ResearchConceptsPrimary plasma cell leukemiaHematopoietic cell transplantationKarnofsky performance statusPlasma cell leukemiaAllo-HCTPPCL patientsCell leukemiaNovel agent eraGood partial responseOutcomes of patientsHigh relapse rateAgent eraHCT utilizationSuperior OSPartial responsePerformance statusInferior survivalMedian ageRelapse rateCell transplantationSEER dataMortality 7Multi-variate analysisPatientsSurvival 17
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDB
2016
Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection
Laurence G, Ahuja V, Bell T, Grim R, Ahuja N. Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection. The American Journal Of Surgery 2016, 214: 432-436. PMID: 28082009, DOI: 10.1016/j.amjsurg.2016.12.018.Peer-Reviewed Original ResearchConceptsMultivisceral resectionAdvanced colorectal cancerColorectal cancerCancer patientsYear survivalNon-metastatic colorectal cancerRadiation treatmentRecto-sigmoid cancerFive-year survivalSignificant associated morbidityKaplan-Meier analysisExtensive surgical proceduresGreatest survival advantageEligible patientsAssociated morbiditySelect patientsMeier analysisStandard surgeryRadical operationSEER dataAdjacent organsSurgical proceduresSurvival advantagePatientsSurgical specialists
2015
Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiation Oncology 2015, 10: 101. PMID: 25902707, PMCID: PMC4464878, DOI: 10.1186/s13014-015-0411-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyDigestive System Surgical ProceduresFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOrganoplatinum CompoundsProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesConceptsRadiation therapyOverall survivalRectal cancerSurveillance EpidemiologyCell carcinomaSEER dataMultivariate Cox proportional hazards modelCox proportional hazards modelBackgroundSmall cell carcinomaMethodsThe SEER databaseCancer-directed therapyEnd Results (SEER) databaseUnadjusted hazard ratioEnd Results (SEER) dataKaplan-Meier methodOverall survival rateYear of diagnosisSmall cell carcinomaSignificant survival advantagePearson's chi-square testProportional hazards modelOnly significant factorChi-square testChemotherapy usageLocoregional cases
2013
Does removal of DCIS decrease the incidence of invasive breast cancer?
Killelea B, Christy C, Horowitz N, Tsangaris T, Dixon M, Chagpar A, Grube B, Lannin D. Does removal of DCIS decrease the incidence of invasive breast cancer? Journal Of Clinical Oncology 2013, 31: 2-2. DOI: 10.1200/jco.2013.31.26_suppl.2.Peer-Reviewed Original ResearchHigh-grade DCISInvasive cancerDCIS componentSEER dataInvasive tumorsHigh-grade invasive cancerLow-grade DCISNon-calcified DCISProportion of DCISPure invasive tumorsInvasive breast cancerPresence of necrosisGrade of DCISLow-grade cancerPresence of calcificationLow gradeDCIS extentMicropapillary histologyGrade DCISPure DCISRetrospective reviewBreast cancerDCISBreast screeningCancer decreases
2012
Demographics of uterine serous cancer (USC) patients: A single institutional experience.
de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.Peer-Reviewed Original ResearchPast medical historyUterine cancerUSC patientsSEER dataBreast cancerPrior historyLargest single-institution experienceCommon uterine cancerSerous cancer patientsSmall institutional seriesSingle institution experienceSingle institutional experienceForms of cancerOlder ptsPt ageDiabetic womenPostmenopausal womenFIGO stageInstitutional seriesOral contraceptivesMenopause statusCancer patientsDisease stageMedical historyEstrogen dependency
2007
Myelodysplastic syndromes
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Cancer 2007, 109: 1536-1542. PMID: 17345612, DOI: 10.1002/cncr.22570.Peer-Reviewed Original ResearchConceptsSurvival of patientsOutcome of MDSMyelodysplastic syndromeDescriptive epidemiologic dataHigh incidence rateIncident casesIncidence rateEpidemiologic dataRisk of MDSPopulation-based databaseEnd Results ProgramCancer Reporting SystemPopulation-based cancer reporting systemsPublic-use databaseMDS survivalWorse survivalMale patientsMDS patientsRefractory anemiaResults ProgramClinical subtypesSEER dataSEER programMDS casesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply